About this company
We are building a native molecular intelligence platform to de-risk and accelerate preclinical drug development in an industry burdened by unsustainable failure rates, costs, and timelines.Our physics-grounded, modular, and data-efficient models can represent any molecular system and have already led to experimentally validated discoveries and accelerations across the preclinical value chain. By improving early-stage decision-making, we help shape better candidates from the start. We have signed LOIs and are negotiating potential contracts with leading biopharma, pursuing a dual-pronged go-to-market strategy: fee-for-service engagements and early-stage-partnerships. Backed by world-class advisors, we are focused on novel molecular formats with transformative therapeutic potential.